Skip to main content

Table 1 Clinical characteristics of mothers with chronic HBV infection

From: Characterization of T cell immunity in chronic hepatitis B virus-infected mothers with postpartum alanine transaminase flare

  AF mothers (n = 6) NAF mothers (n = 14) P value
Age (years) 30.00 (25.25, 33.75) 27.00 (26.00, 29.00) 0.25
Gravidity 1.00 (1.00, 1.50) 1.00 (1.00, 2.00)  > 0.99
Parity 1.00 (1.00, 1.50) 1.00 (1.00, 1.25)  > 0.99
Delivery gestations (weeks) 39.00 (38.75, 39.25) 40.00 (38.00, 40.00) 0.5
Duration of AVT (days) 101.00 (91.00, 105.30) 95.00 (79.25, 105.80) 0.44
Type of delivery—no. (%)    
 Vaginal 5 (83.33%) 11 (78.57%)  > 0.99
 Caesarean section 1 (16.67%) 3 (21.43%)  
Before AVT (gestational 26–28 weeks)    
 ALT(U/L) 22.00 (15.50, 23.50) 21.00 (15.75, 24.25) 0.7
 AST(U/L) 21.00 (16.50, 29.00) 19.00 (16.75, 21.25) 0.54
Gestational 30–32 weeks    
 ALT(U/L) 27.50 (16.00, 47.00) 16.00 (12.75, 25.25) 0.15
 AST(U/L) 29.00 (22.75, 34.00) 20.59 (16.00, 22.00) 0.05
Delivery    
 ALT(U/L) 17.50 (11.00, 24.50) 18.00 (13.00, 20.00) 0.94
 AST(U/L) 22.00 (15.25, 25.25) 21.00 (16.25, 25.75) 0.98
Postpartum 6–8 weeks    
 ALT(U/L) 38.00 (30.25, 98.50) 38.00 (18.75, 47.75) 0.41
 ALT(n, > 2 × ULN) 2 (33.33%) 0 0.08
 AST(U/L) 29.50 (19.00, 86.50) 25.50 (19.00, 36.00) 0.51
 AST(n, > 2 × ULN) 2 (33.33%) 0 0.08
Postpartum 15–18 weeks    
 ALT(U/L) 106.60 (40.00, 215.80) 28.00 (23.50, 46.00) 0.03
 ALT(n, > 2 × ULN) 4 (66.67%) 0 0
 AST(U/L) 57.00 (33.75, 158.50) 24.00 (21.00, 30.00) 0
 AST(n, > 2 × ULN) 2 (33.33%) 0 0.08
  1. Data are shown as median (IQR interquartile range)
  2. AVT antepartum antiviral therapy; ALT alanine transaminase; AST aspartate aminotransferase